A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin: Flex T1)

Trial Profile

A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin: Flex T1)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms BEGIN
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2012 Extension study results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 05 Oct 2012 Results comparing efficacy and tolerability of the 2 insulin degludec dosing regimens presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top